Scientists Find Way to Stop Common Vision Loss

For the first time, scientists have found a way to protect the cells that keep our central vision sharp.

Researchers at the Institute of Molecular and Clinical Ophthalmology Basel tested over 2,700 compounds on 20,000 human retinal organoids, lab-grown tissue that mimics real eyes. They discovered several molecules that shield cone photoreceptors from dying, the kind of cell death that causes vision loss in age-related macular degeneration and inherited retinal disorders.

Cone cells live in the macula, the part of the eye we use for reading, driving, and seeing the faces of people we love. When these cells die, central vision fades to black. More than 11 million Americans have macular degeneration, yet no approved treatments exist to stop the progression.

The research team, led by Botond Roska and first authors Stefan Spirig and Alvaro Herrero Navarro, labeled cone cells with fluorescent markers to track their survival under stress conditions that mimic disease. This allowed them to systematically test which compounds kept the cells alive and which ones caused harm.

Two kinase inhibitors showed especially strong protective effects, keeping cone cells alive across different stress conditions. The team confirmed these results in mice with retinal degeneration, suggesting the approach could work in living eyes, not just lab dishes.

The discovery goes beyond identifying helpful compounds. The researchers also flagged certain classes of molecules that actively harm cone cells, raising important safety warnings for drug developers working on eye treatments.

The Ripple Effect

The team made their entire dataset public, sharing detailed information on all 2,700 compounds tested, their molecular targets, and their effects on human retinal tissue. This open access resource means researchers worldwide can now build on these findings without starting from scratch.

Drug developers can use the data to design safer medications that avoid harming delicate retinal cells. Scientists studying vision can explore new pathways to protect photoreceptors. The dataset essentially provides a roadmap for the next generation of treatments aimed at preserving sight.

The research combines three powerful tools: advanced understanding of retinal biology, human organoid technology that eliminates some need for animal testing, and large-scale screening that would have been impossible a decade ago. Together, they create a foundation for therapies that could preserve vision for millions.

The work brings researchers closer to a goal that has eluded eye doctors for generations: stopping vision loss before it steals the ability to see clearly.